| __timestamp | BeiGene, Ltd. | Takeda Pharmaceutical Company Limited |
|---|---|---|
| Wednesday, January 1, 2014 | 6930000 | 612613000000 |
| Thursday, January 1, 2015 | 7311000 | 650773000000 |
| Friday, January 1, 2016 | 20097000 | 619061000000 |
| Sunday, January 1, 2017 | 62602000 | 628106000000 |
| Monday, January 1, 2018 | 195385000 | 717599000000 |
| Tuesday, January 1, 2019 | 388249000 | 964737000000 |
| Wednesday, January 1, 2020 | 600176000 | 875663000000 |
| Friday, January 1, 2021 | 990123000 | 886361000000 |
| Saturday, January 1, 2022 | 1277852000 | 997309000000 |
| Sunday, January 1, 2023 | 1504501000 | 1053819000000 |
| Monday, January 1, 2024 | 1053819000000 |
Unveiling the hidden dimensions of data
In the ever-evolving pharmaceutical landscape, understanding the financial dynamics of industry leaders is crucial. This analysis delves into the Selling, General, and Administrative (SG&A) expenses of Takeda Pharmaceutical Company Limited and BeiGene, Ltd. over the past decade.
From 2014 to 2023, Takeda's SG&A expenses have shown a consistent upward trend, peaking at approximately 1.05 trillion yen in 2023. This represents a 72% increase from 2014, reflecting Takeda's strategic investments in global expansion and innovation.
In contrast, BeiGene's SG&A expenses have skyrocketed, growing over 200 times from 2014 to 2023. This exponential rise underscores BeiGene's aggressive market penetration and R&D efforts.
While Takeda's growth is steady, BeiGene's rapid increase highlights its ambition to challenge established players. Investors and stakeholders should watch these trends closely as they signal strategic shifts in the pharmaceutical sector.
Takeda Pharmaceutical Company Limited vs Intra-Cellular Therapies, Inc.: SG&A Expense Trends
Selling, General, and Administrative Costs: Takeda Pharmaceutical Company Limited vs Insmed Incorporated
Operational Costs Compared: SG&A Analysis of Takeda Pharmaceutical Company Limited and Pharming Group N.V.
Takeda Pharmaceutical Company Limited and TG Therapeutics, Inc.: SG&A Spending Patterns Compared
Breaking Down SG&A Expenses: Takeda Pharmaceutical Company Limited vs Lantheus Holdings, Inc.
SG&A Efficiency Analysis: Comparing Takeda Pharmaceutical Company Limited and Perrigo Company plc
Cost Management Insights: SG&A Expenses for Takeda Pharmaceutical Company Limited and Galapagos NV
Cost Management Insights: SG&A Expenses for Takeda Pharmaceutical Company Limited and MiMedx Group, Inc.
SG&A Efficiency Analysis: Comparing BeiGene, Ltd. and Summit Therapeutics Inc.
SG&A Efficiency Analysis: Comparing BeiGene, Ltd. and Pharming Group N.V.
Comparing SG&A Expenses: BeiGene, Ltd. vs ADMA Biologics, Inc. Trends and Insights
Operational Costs Compared: SG&A Analysis of BeiGene, Ltd. and Mesoblast Limited